Clinical Trial Update: Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting results for durvalumab in combination with platinum and etoposide as first-line therapy for extensive-stage small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-08-20